GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Windlas Biotech Ltd (NSE:WINDLAS) » Definitions » Debt-to-Asset

Windlas Biotech (NSE:WINDLAS) Debt-to-Asset : 0.00 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Windlas Biotech Debt-to-Asset?

Windlas Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0 Mil. Windlas Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0 Mil. Windlas Biotech's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was ₹0 Mil.


Windlas Biotech Debt-to-Asset Historical Data

The historical data trend for Windlas Biotech's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Windlas Biotech Debt-to-Asset Chart

Windlas Biotech Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-Asset
Get a 7-Day Free Trial 0.09 0.11 0.01 0.01 0.01

Windlas Biotech Quarterly Data
Mar19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.01 - 0.03 -

Competitive Comparison of Windlas Biotech's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Windlas Biotech's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Windlas Biotech's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Windlas Biotech's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Windlas Biotech's Debt-to-Asset falls into.


;
;

Windlas Biotech Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Windlas Biotech's Debt-to-Asset for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(16.23 + 20.18) / 6262.06
=0.01

Windlas Biotech's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Windlas Biotech  (NSE:WINDLAS) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Windlas Biotech Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Windlas Biotech's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Windlas Biotech Business Description

Traded in Other Exchanges
Address
Golf Course Extension Road, 705-706, Vatika Professional Point, Sector-66, Gurgaon, HR, IND, 122 001
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.

Windlas Biotech Headlines

No Headlines